Evaluation of Smoking as a Modifying Factor in Chronic Rhinosinusitis.


Journal

JAMA otolaryngology-- head & neck surgery
ISSN: 2168-619X
Titre abrégé: JAMA Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 101589542

Informations de publication

Date de publication:
01 02 2021
Historique:
pubmed: 11 12 2020
medline: 24 4 2021
entrez: 10 12 2020
Statut: ppublish

Résumé

The negative association of smoking with the respiratory tract is well known; however, the association between smoking and chronic rhinosinusitis (CRS) has not been well characterized. To analyze whether active smoking was a risk factor for CRS development, smoking was associated with disease-specific quality of life, and smokers experience an increased symptom burden than nonsmokers. This subanalysis of the Chronic Rhinosinusitis Epidemiology Study (CRES), a prospective, questionnaire-based case-control study conducted between October 2007 and September 2013 was conducted across 30 UK tertiary/secondary care sites. Participants were identified at ear, nose, and throat outpatient clinics and classified into CRS phenotypes as per European Position Paper on Rhinosinusitis and Nasal Polyps 2012 criteria. The overall response rate of those identified to take part in the study was 66%. A total of 1535 questionnaires were returned, with 1470 considered eligible for inclusion. Data analysis was conducted in January 2020. The CRES was designed to distinguish differences in socioeconomic status, geography, medical comorbidities, lifestyle, and quality of life between patients with CRS and healthy controls. A total of 1450 patients completed the smoking question, comprising 219 controls (15.1%; mean [SD] age, 47.3 [14.9] years; 143 women [68%]), 546 participants with CRS (37.7%; mean [SD] age, 51.8 [15.3] years; 259 women [53%]) without nasal polyps (CRSsNPs), and 685 participants (47.2%; mean [SD] age, 56.0 [14.5] years; 204 women [33%]) with CRS and nasal polyps/allergic fungal rhinosinusitis (CRSwNPs+). The mean age was similar, with a greater female preponderance in the control group and male in the CRSwNP group. The greatest number of active smokers was found among control participants (33 [15%]), with a lower rate of smokers in the patients with CRSwNPs+ (9.9%) and CRSsNPs (13.9%), respectively. We found a clinically significant difference in the mean difference in Sino-nasal Outcome Test (SNOT-22) scores between active smokers and nonsmokers for both CRS phenotypes (4.49, 12.25). In both CRS subgroups active smokers had significantly worse SNOT-22 scores than nonsmokers by a mean (SD) magnitude of 10 (18.99, 24.14) points. Nonsmokers also demonstrated a higher percentage of surgical procedures (1 or more), although this was not clinically or statistically different (0.34, 1.10). This questionnaire-based case-control study demonstrated a clinically significant symptom burden associated with active cigarette smoking, with worse SNOT-22 scores in the smoking cohort by a mean magnitude of 10 points. We could find no demonstrable evidence that smoking increases the likelihood of need for revision sinus surgery. Clinicians should encourage smoking cessation alongside general CRS medical management.

Identifiants

pubmed: 33300989
pii: 2774085
doi: 10.1001/jamaoto.2020.4354
pmc: PMC7729579
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-165

Auteurs

Kristian Hutson (K)

James Paget University Hospital National Health Service (NHS) Foundation Trust, Gorleston, England.

Allan Clark (A)

Norwich Medical School, University of East Anglia, Norfolk, England.

Claire Hopkins (C)

Guys & St Thomas Hospital NHS Foundation Trust, London, England.

Shahzada Ahmed (S)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, England.

Nirmal Kumar (N)

Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, England.

Sean Carrie (S)

Freeman Hospital, Newcastle, England.

Sally Erskine (S)

James Paget University Hospital National Health Service (NHS) Foundation Trust, Gorleston, England.

Vishnu Sunkaraneni (V)

Royal Surrey County Hospital, Guildford, England.

Carl Philpott (C)

James Paget University Hospital National Health Service (NHS) Foundation Trust, Gorleston, England.
Norwich Medical School, University of East Anglia, Norfolk, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH